Skip to main content
Caplight Logo









NuvOx Therapeutics

NuvOx Therapeutics

Private
Tucson, ArizonaHealthcare & Life Scienceshttps://www.nuvoxtherapeutics.com/

Last Round

Grant

Sep 26, 2025

Total Funding Raised

$20.69M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

NuvOx Therapeutics is a clinical-stage biopharmaceutical company developing a first-in-class oxygen therapeutic designed to reverse tissue hypoxia in life-threatening diseases such as cancer, stroke, and respiratory distress.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2G

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

oxygen therapeutictissue hypoxiaclinical-stage biotechoxygen carrierstroke treatmentoncologyfirst-in-class therapeuticradiation sensitizerneuroprotectantacute respiratory distress syndromeARDSperfluorocarbon emulsiondodecafluoropentane emulsionbiologic drugintravenous drugGMP manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NuvOx Therapeutics Comparables

Compare NuvOx Therapeutics with similar companies based on industry and business-model similarity.

NuvOx Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Prolong Pharmaceuticals, LLC
88%
Omniox, Inc.
83%
Aurum Biosciences Ltd
81%

NuvOx Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 26, 2025
Convertible DebtSep 18, 2023
GrantFeb 11, 2022
GrantApr 12, 2017
GrantOct 17, 2014

Key People

Founding team and executive leadership

J Johnson

Chief Financial Officer

Executive Team

Jennifer L.H. Johnson

Chief Operating Officer

Executive Team

NuvOx Therapeutics Investors

Notable investors and investment history

NuvOx Therapeutics investors
InvestorRounds
National Cancer InstituteGrant
Gulf South AngelsConvertible Debt
VisionTech PartnersConvertible Debt
U.S. Department of WarGrant
MEDA AngelsConvertible Debt
National Heart, Lung, and Blood InstituteGrant
New World AngelsConvertible Debt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 26, 2025

    $2M grant from the National Cancer Institute

  • Jul 23, 2025

    Grew 30% QoQ, from 10 to 13 employees.

NuvOx Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NuvOx Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NuvOx Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersTucson, Arizona
Employee Range14
Year Founded2008
Last FundingSep 26, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?